Changes in circulating thyroid hormones during short-term hepatic enzyme induction with carbamazepine

Area of Science:

• Pharmacology
• Endocrinology
• Hepatology

Background:

• Carbamazepine (CBZ) is an anticonvulsant known to induce hepatic enzymes.
• Hepatic enzyme induction can affect the metabolism of various endogenous substances, including hormones.
• The impact of short-term CBZ therapy on thyroid hormone homeostasis requires further elucidation.

Purpose of the Study:

• To investigate the effect of short-term hepatic enzyme induction by carbamazepine (CBZ) on circulating thyroid hormone levels.
• To assess the impact of CBZ on the pituitary/thyroid axis by measuring thyroid-stimulating hormone (TSH) response.

Main Methods:

• 10 healthy male subjects received CBZ (400 mg/day) for 14 or 21 days.
• Hepatic enzyme activity was assessed by antipyrine half-life and clearance.
• Serum concentrations of total thyroxine (T4), triiodothyronine (T3), free T4, reverse T3, and TSH were measured.

Main Results:

• CBZ significantly induced hepatic monooxygenase activity, indicated by decreased antipyrine half-life and increased clearance.
• Significant reductions were observed in total T4, T3, and free T4 levels post-CBZ therapy.
• No significant changes were found in reverse T3, thyroid binding globulin, or TSH response to thyrotrophin-releasing hormone.

Conclusions:

• Short-term CBZ therapy induces hepatic enzyme activity, leading to accelerated disposal of thyroid hormones.
• The observed decrease in thyroid hormones is likely due to enhanced hepatic metabolism.
• The lack of TSH response to reduced thyroid hormone levels suggests complex regulatory mechanisms that warrant further investigation for chronic CBZ use.